• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

Box-Behnken效应面法优化盐酸普拉克索缓释片处方及体外释放机制

康振华, 陈远东, 徐成, 游剑, 秦民坚, 秦勇

康振华, 陈远东, 徐成, 游剑, 秦民坚, 秦勇. Box-Behnken效应面法优化盐酸普拉克索缓释片处方及体外释放机制[J]. 中国药科大学学报, 2015, 46(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20150108
引用本文: 康振华, 陈远东, 徐成, 游剑, 秦民坚, 秦勇. Box-Behnken效应面法优化盐酸普拉克索缓释片处方及体外释放机制[J]. 中国药科大学学报, 2015, 46(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20150108
shu
KANG Zhenhua, CHEN Yuandong, XU Cheng, YOU Jian, QIN Minjian, QIN Yong. Optimization of pramipexole hydrochloride sustained-release tablets using Box-Behnken design and mechanism of in vitro drug release[J]. Journal of China Pharmaceutical University, 2015, 46(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20150108
Citation: KANG Zhenhua, CHEN Yuandong, XU Cheng, YOU Jian, QIN Minjian, QIN Yong. Optimization of pramipexole hydrochloride sustained-release tablets using Box-Behnken design and mechanism of in vitro drug release[J]. Journal of China Pharmaceutical University, 2015, 46(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20150108
shu

Box-Behnken效应面法优化盐酸普拉克索缓释片处方及体外释放机制

  • 1.

    中国药科大学中药学院

  • 2.

    江苏神龙药业有限公司

基金项目: 江苏省“创新团队计划”(科技类)资助项目

Optimization of pramipexole hydrochloride sustained-release tablets using Box-Behnken design and mechanism of in vitro drug release

摘要

    摘要
  • 摘要: 通过单因素试验筛选盐酸普拉克索缓释片处方，采用Box-Behnken效应面法优化处方并制备盐酸普拉克索缓释片。单因素试验考察羟丙基甲基纤维素(HPMC)不同型号、不同用量及与不溶性缓释材料组合使用对盐酸普拉克索缓释片体外释放度的影响。确定以HPMC K100M、Eudragit RSPO、Eudragit L100为主要考察因素，以不同时间的累积释放度为评价指标。Box-Behnken效应面法优化处方得出三者的最优范围，以其中优选处方HPMC K100M 101.5 mg、Eudragit RSPO 98 mg和Eudragit L100 13.7 mg和其他辅料制备盐酸普拉克索缓释片并考察释放度。通过相似因子计算，优选处方的体外累积释放度预测值和实测值相似度均大于80。对体外释药数据进行方程拟合，探讨其释药机制，Eudragit RSPO促进盐酸普拉克索的释放，Eudragit L100阻滞盐酸普拉克索的释放，二者互为拮抗作用。结果表明，该处方制备的普拉克索缓释片pH依赖性小，体外释放行为稳定，实现了该缓释片的处方优化。
    Abstract: The formulations of pramipexole hydrochloride sustained-release tablets were screened by single factor test and optimized by Box-Behnken design. The effects of the viscosity and content of hydroxypropyl methyl cellulose, as well as the insoluble sustained-release material combined with HPMC K100M on the in vitro release behavior were investigated. After single factor screening, a three-factor, three-level Box-Behnken design was used for optimization using the contents of HPMC K100, Eudragit RSPO and Eudragit L100 as independent variables, and the cumulative release at different time as responses. The optimal range of the three-factor optimized by Box-Behnken design, one of the optimized formulations was achieved with HPMC K100M of 101. 5 mg, Eudragit RSPO of 98 mg, and Eudragit L100 of 13. 7 mg, and the observed responses of the optimized formulation were very close to the predicted values. The in vitro drug release mechanism of the tablet was studied by drug released model fitted with different equations. The results explained that Eudragit RSPO promoted the release of the pramipexole hydrochloride, while Eudragit L100 blocked the release, and there was an antagonism between them. In conclusion, the drug release behavior of optimized formulations prepared by Eudragit RSPO/L100 was stable, less pH-dependent, which improved the drug bioavailability in vivo.
    • HTML全文
    • 参考文献(6)
  • [1] Wang XN,Liu GD,Xiao Q,et al.Observation of curative effect of dopamine receptor antagonist pramipexole for treatment on non-motor symptoms of Parkinson′s disease[J].J Clin Neur(临床神经病学杂志),2010,23(4):299-301.
    [2] Chwieduk CM,Curran MP.Pramipexole extended release[J].CNS drugs,2010,24(4):327-336.
    [3] Thomas F.Preparation and use of pramipexole hydrochloride sustained-release tablets:CN,101005830B[P].2010-09-29[2014-06-09] .
    [4] Wang XD,Liu K,LiQ K,et al.Optimized formulation of levofloxacin gastric floating tablet by Box-Behnken design[J].Chin J Mod Appl Pharm(中国现代应用药学),2013,30(4):406-411.
    [5] Deepan T,Paulambethkar K,Vijayalakshmi R,et al.A validated RP-HPLC method for the estimation of pramipexole dihydrochloride in pH armaceutical dosage form[J].World J Chem,2012,7(2):59-63.
    [6] Sekhar KS,Nagabhushanam MV,Rao KRSS,et al.Formulation development and in vivo evaluation of pramipexole dihydrochloride monohydrate extended release tablets for Parkinson′s disease[J].Der Pharm Lett J,2013,5(4):153-163.
    • 相关文章
    • 施引文献(9)

  • 期刊类型引用(4)

    1. 宋永真，李雅静，张振凌，王胜超. 曼地亚红豆杉酒炙工艺及质量标准研究. 中医学报. 2024(05): 1068-1075 . 百度学术
    2. 剡槿熙，臧明伍，刘贺，徐晨晨，史宇璇，白京，赵燕，郝静怡，张亚茹. 二萜类化合物在肉类食品保鲜防腐中的应用研究进展. 食品科学. 2024(13): 282-291 . 百度学术
    3. 王楠楠，蔡婷婷，童晔玲，刘霞，朱婉萍，江石平，赵桂芝. 基于NF-κB信号通路的HTRF法筛选红豆杉中抗气道炎症有效活性成分研究. 浙江中医杂志. 2023(08): 553-556 . 百度学术
    4. 傅贵江. 杉木人工林抚育间伐对套种南方红豆杉的影响. 武夷科学. 2022(01): 39-43 . 百度学术

    其他类型引用(5)

    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 9
出版历程
  • 刊出日期:  2015-02-24

目录

摘要
HTML全文
    参考文献(6)
    相关文章
    施引文献(9)
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：400387

    x 关闭 永久关闭